Poseida Therapeutics' (PSTX) Buy Rating Reiterated at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Poseida Therapeutics (NASDAQ:PSTX – Free Report) in a research note published on Wednesday, Benzinga reports. HC Wainwright currently has a $20.00 target price on the stock. HC Wainwright also issued estimates for Poseida Therapeutics’ Q2 2024 earnings at ($0.43) EPS, Q3 2024 earnings at ($0.46) EPS, […]

Related Keywords

Ohio , United States , , Mirae Asset Global Investments Co , Poseida Therapeutics Inc , Silverarc Capital Management , Nasdaq , Barclays Plc , Poseida Therapeutics , Free Report , Get Free Report , Capital Management , Employees Retirement System , Asset Global Investments , Heme Malignancies , Poseida Therapeutics Daily ,